Previous Article | Next Article ![]()
Molecular and Cellular Biology, October 2001, p. 6615-6625, Vol. 21, No. 19
Department of Molecular Oncology1
and Department of Nutrition and Physiological
Chemistry,3 Osaka University Graduate School
of Medicine, Suita, Osaka 565-0871, and Department of
Immunology, Osaka City University Graduate School of Medicine,
Osaka 545-8485,2 Japan
Received 7 March 2001/Returned for modification 21 May
2001/Accepted 2 July 2001
Signal transducer and activator of transcription 3 (STAT3) mediates
signals of various growth factors and cytokines, including interleukin-6 (IL-6). In certain IL-6-responsive cell lines, the stat3 gene is autoregulated by STAT3 through a composite
IL-6 response element in its promoter that contains a STAT3-binding element (SBE) and a cyclic AMP-responsive element. To reveal the nature
and roles of the stat3 autoregulation in vivo, we
generated mice that harbor a mutation in the SBE
(stat3mSBE). The intact SBE was
crucial for IL-6-induced stat3 gene activation in the
spleen, especially in the red pulp region, the kidney, and both mature
and immature T lymphocytes. The SBE was not required, however, for
IL-6-induced stat3 gene activation in hepatocytes. T
lymphocytes from the stat3mSBE/mSBE
mice were more susceptible to apoptosis despite the presence of IL-6
than those from wild-type mice. Consistent with this, IL-6-dependent
activation of the Pim-1 and junB genes,
direct target genes for STAT3, was attenuated in T lymphocytes of the stat3mSBE/mSBE mice. Thus, the
tissue-specific autoregulation of the stat3 gene operates in vivo and plays a role in IL-6-induced antiapoptotic signaling in T cells.
Signal transducers and activators of
transcription (STATs) have been shown to play key roles in transmitting
growth factor and cytokine signals (8, 14, 18; see also
reviews in Oncogene [19]). Upon stimulation
of the receptors for a variety of cytokines and some growth factors,
members of the STAT family, which are present in the cytoplasm in
latent form, are recruited to the tyrosine-phosphorylated receptors
through their SH2 domains, where they can be activated by the
receptor-associated Janus kinases (JAKs), receptor tyrosine kinases,
and, in some cases, cytoplasmic tyrosine kinases (3).
Tyrosine-phosphorylated STATs form homo- and heterodimers, enter the
nucleus, and activate the transcription of target genes by binding to
the specific DNA element TTN5AA (9,
35).
STAT3 is involved in various biological responses elicited by the
interleukin-6 (IL-6) family of cytokines (14, 15), some growth factors, including epidermal growth factor (EGF), and v-Src (3). STAT3 plays a critical role in IL-6/gp130-induced
cell growth and differentiation and in the survival of cultured cells (4, 12, 13, 21, 24, 26, 36, 43). STAT3 is also required
for the leukemia inhibitory factor-mediated maintenance of the
pluripotency of mouse embryonic stem (ES) cells (2, 28)
and for ciliary neurotrophic factor-mediated astrocyte differentiation (44). The stat3 gene has been disrupted in mice
by conventional and conditional gene knockout methods. These studies
reveal a variety of roles for STAT3 in vivo, including roles in early
embryogenesis, IL-6-mediated antiapoptosis in T cells, IL-10-induced
repression of inflammatory responses in macrophages, wound healing,
development of secondary hair follicles in the skin, and apoptosis of
mammary gland epithelial cells (5, 32, 37-39).
Several negative regulatory mechanisms have been postulated, especially
at the level of STAT3 activation. A mutation in the SHP2-binding motif,
pYSTV, in gp130 in mice causes prolonged activation of STAT3,
suggesting that SHP2-mediated signals negatively regulate STAT3
(29). The expression of the mRNA for SOCS3 (suppressor of
cytokine signaling 3), a member of the SOCS/JAB/SSI family, was
recently shown to inhibit STAT3 activation by binding to the phosphorylated YSTV motif in gp130, causing negative feedback (27, 34). One of the PIAS (protein inhibitor of activated STAT) family proteins, PIAS3, inhibits STAT3's function by binding to
dimerized STAT3, thus blocking STAT3's DNA-binding activity (6). Pretreatment with tetradecanoyl phorbol acetate
(TPA), which activates extracellular signal-regulated kinase and
protein kinase C (PKC), or nerve growth factor (NGF) inhibits the
IL-6-induced STAT3 tyrosine phosphorylation (7, 17).
In contrast, a positive regulatory mechanism has been reported only at
the level of stat3 gene expression. Treatment of mice with
IL-6 increases the level of stat3 mRNA in the liver
(1). We have reported that IL-6 induces stat3
mRNA in cell lines through an IL-6 response element in the promoter
containing both a low-affinity STAT3-binding element (SBE) and a cyclic
AMP-responsive element (CRE) (16). This result suggested
that STAT3 is likely to be involved in maintaining the duration and
strength of STAT3-mediated signals by activating its own gene expression.
In this study, we addressed the question of whether the autoregulation
of stat3 gene activation through the low-affinity SBE could
be demonstrated in vivo. We generated a line of mice that harbor a
mutation in the low-affinity SBE in the stat3 gene promoter (mSBE) by homologous recombination. The intact SBE was required for
IL-6-induced stat3 gene activation in the spleen,
particularly in the red pulp region, and in the kidney and T cells, but
not in hepatocytes. Furthermore, the autoregulatory activation of the
stat3 gene was involved in IL-6-induced T-cell survival.
Generation of knockin mice.
A genomic DNA fragment of the
murine stat3 gene was isolated from a
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.19.6615-6625.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Tissue-Specific Autoregulation of the
stat3 Gene and Its Role in Interleukin-6-Induced
Survival Signals in T Cells


![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
fix II 129/sv
mouse genomic library (Stratagene) using a 2.2-kb genomic fragment of
the stat3 promoter as a probe (16). A 7-kb
fragment containing the 3 kb of the 5' region, the first exon, and a
part of the first intron was subcloned into the SalI and
BamHI sites of pBluescriptII SK+ (Stratagene) to make
pBS-stat3. pBS-wtSBE was made by subcloning the 0.25-kb SacI
fragment of pBS-stat3, which contains the IL-6 response element, into
the SacI site of pBluescriptII SK+. The IL-6 response
element is composed of an SBE, located at
338 to
331 upstream of
the transcriptional initiation site, and a typical CRE
(16). To make pBS-mSBE, a mutation was introduced into the
SBE of pBS-wtSBE by PCR-mediated mutagenesis using a QuickChange
site-directed mutagenesis kit (Stratagene) according to the
manufacturer's protocol; the resulting mutant SBE has an
NcoI site. To make pBS-stat3mSBE, the SacI
fragment in the stat3 promoter in pBS-stat3 was replaced by
the SacI fragment from pBS-mSBE. The primers used for the
mutagenesis were 5'-CAC GCA CTG CCA TGG TTT CAG CTG AG-3'
and 5'-CTC AGC TGA-AAC CAT GGC AGT GCG TG-3'.
-geo,
consisting of a splice acceptor (SA),
-galactosidase-neomycin resistance gene (
-geo) (10), and two loxP
sites at the 5' and 3' ends, was inserted into the SpeI
sites in the first intron and a herpes simplex virus thymidine kinase
gene was inserted into the SphI and BamHI sites
of pBS-stat3 and of pBS-stat3mSBE, resulting in pBS-stat3wtSBE
-geo
and pBS-stat3mSBE
-geo, respectively (Fig.
1A). R1 ES cells were
transfected with pBS-stat3wt
-geo and pBS-stat3mSBE
-geo to create
the stat3wtSBE
-geo and
stat3mSBE
-geo alleles,
respectively. The transfected cells were selected with G418 at 400 µg/ml and ganciclovir at 2 µM. Homologous recombination in the ES
cells was confirmed by Southern blot analysis of
BamHI-digested genomic DNA with a 0.5-kb
EcoRI-BamHI fragment of pBS-stat3 as a 3' probe.
In this analysis, a 2.0-kb hybridized fragment was detected in DNA
samples from ES cells that underwent homologous recombination and an
8.0-kb hybridized fragment was detected from the DNA of ES cells that
underwent random integration (Fig. 1C). To detect the
stat3mSBE
-geo allele,
NcoI-digested genomic DNA from ES cells with homologous recombination was further subjected to Southern blot analysis using the
0.4-kb SpeI fragment of pBS-stat3 as an internal probe. In
this analysis, digestion of the
stat3wtSBE
-geo,
stat3mSBE
-geo, and
wild-type alleles created 8.0-, 4.0-, and 7.0-kb hybridized fragments,
respectively (Fig. 1D).

View larger version (30K):
[in a new window]
FIG. 1.
Generation of knockin mice. (A) Schematic diagram of the
endogenous locus for the stat3 gene, knockin vectors,
and targeted allele. The knockin vectors have a splice acceptor
(SA)-
-geo gene flanked with two loxP sequences in the
first intron (pBS-stat3wt
-geo). The mutant promoter has a mutated
STAT3-binding site with an NcoI site (underlined, left
panel, at bottom). Arrowheads indicate the bases that were altered. The
alleles for the targeting vectors were designated
stat3wtSBE
-geo and
stat3mSBE
-geo,
respectively. The SA and
-geo cassette were removed by crossing
stat3mSBE
-geo mice with
CAG-cre transgenic mice, resulting in the generation of the
stat3mSBE allele (right panel, at
bottom). E, EcoRI; N, NcoI; Spe, SpeI; B,
BamHI; Sph, SphI; TK, thymidine kinase.
(B) Loss of IL-6 responsiveness of the mutated STAT3-binding site. We
made reporter constructs containing the minimal junB
promoter and the luciferase gene (Luc) with either the wild-type
STAT3-binding site from the 5' region of the stat3 gene,
wtSBE Luc, or the mutated binding site, mSBE Luc (left). These were
transiently transfected into HepG2 cells and stimulated with IL-6 (open
bars) for 5 h or left unstimulated (solid bars). Luciferase
activity was normalized to
-galactosidase activity, and averages
from triplicate experiments are shown (right). (C) Southern blot
analysis of targeted ES clones. BamHI-digested DNA from
wild-type ES clones (+/+), targeted clones with the
wild-type promoter
(stat3+/wtSBE
-geo), and
the mutated promoter
(stat3+/mSBE
-geo) were
hybridized with the 3' probe shown in A (right panel, at top). (D)
Detection of the mutated STAT3-binding site by Southern blot.
NcoI-digested DNA from
stat3+/wtSBE
-geo and
stat3+/mSBE
-geo ES
clones was hybridized with the internal probe shown in A (right panel,
at top).
-geo or
stat3mSBE
-geo allele.
F1
stat3+/mSBE
-geo
heterozygous mice were mated with CAG-cre transgenic mice that ubiquitously expressed Cre recombinase (31) so that the
floxed SA
-geo fragment was deleted from the
stat3mSBE
-geo allele,
generating heterozygous mice with the
stat3+/mSBE genotype. The presence of the
stat3mSBE allele was determined by
Southern blot analysis using genomic DNA digested with EcoRI
or NcoI and the internal probe. The wild-type, stat3mSBE
-geo, and
stat3mSBE alleles generated, respectively,
a 6.0-, 9.2-, and 4.0-kb hybridized fragment in the
EcoRI digestion. The wild-type and
stat3mSBE alleles generated a 7.0- and a
4.0-kb fragment in the NcoI digestion, respectively.
F2 stat3+/mSBE mice
were intercrossed to generate F3 homozygous
mice with a stat3mSBE/mSBE genotype.
To test the ability of the SacI fragments bearing either the
mSBE or the wild-type SBE to respond to IL-6 in HepG2 cells, each
0.25-kb SacI fragment containing wtSBE or mSBE was inserted into pSP-Luc upstream of the minimal junB
promoter linked with the luciferase gene (22). HepG2 cells
were transfected with DNA mixtures by the standard calcium phosphate
precipitation method. Typically, 1.2 µg of one of the reporter
plasmids, 1 µg of pEFLacZ, a pEF-BOS expression vector containing the
lacZ gene encoding
-galactosidase as an internal control
for transfection efficiency, and 3 µg of pEF-BOS, as carrier DNA,
were used. Forty-two hours after the transfection, cells were
stimulated with IL-6 (100 ng/ml) for 6 h, harvested, and subjected
to assays for luciferase and
-galactosidase activity as described
previously (22).
-Galactosidase staining, measurement of
-galactosidase
activity, and immunohistochemistry.
For
-galactosidase
staining, tissue samples were fixed in 2% formaldehyde and
0.2% glutaraldehyde in phosphate-buffered saline (PBS) containing
0.1% NP-40 for 30 min and frozen in OCT compound (Sakura
Finetechnical). Ten-micrometer-thick frozen sections were prepared and
stained with 0.1%
5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside (X-Gal)
in PBS solution containing 2 mM MgCl2, 5 mM
K3Fe(CN6), and 5 mM
K4Fe(CN6) at room
temperature for the indicated period of time. Counterstaining was done
with Nuclear Fast Red (Vector).
-galactosidase antibody (Cappel). After
washing, the sections that had been incubated with primary antibody
against
-galactosidase were stained with Alexa Fluor 488-conjugated
goat anti-rabbit immunoglobulin G) (IgG; Molecular Probes), and the
sections incubated with primary antibody against CD31 were reacted with
biotinylated donkey anti-rat IgG (Jackson ImmunoResearch). Sections
were then washed with 0.05% Triton X-100 in PBS and stained with
rhodamine-conjugated avidin for biotinylated antibody.
The
-galactosidase activity of each tissue homogenate (30 µg of
protein) was measured in triplicate, and relative activity was obtained
by dividing the average activity of
+/stat3mSBE
-geo mice with that of
+/stat3wtSBE
-geo mice without
IL-6 stimulation.
Northern blot analysis. Total RNA was extracted using the Sepazol I reagent (Nakarai-tesque). Twenty micrograms of total RNA was fractionated on 1% agarose gels containing formaldehyde and transferred to Hybond N+ membranes (Amersham Pharmacia Biotech). The membranes were hybridized with 32P-labeled cDNA fragments overnight, washed three times with 0.2× SSC (1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-0.1% sodium dodecyl sulfate (SDS) at 56°C and subjected to autoradiography. The amounts of RNA loaded were verified by ethidium bromide staining. The probes used were the 2.5-kb SalI-BamHI fragment of pBSHA-stat3 containing the stat3 cDNA (24), a 1.0-kb EcoRI-XhoI fragment of Pim-1 cDNA (36), and a 1.5-kb EcoRI fragment of junB cDNA.
Preparation of lymph node and splenic T cells. Splenocytes were treated with 0.165 M NH4Cl to lyse erythrocytes. Splenic T and lymph node T cells were enriched with anti-CD90 antibody-conjugated magnetic beads (Miltenyi biotec) and a Mini MACS column (Miltenyi biotec). The purity of the isolated T cells was determined by staining cells with a phycoerythrin-conjugated anti-CD3 monoclonal antibody (145-2C11; PharMingen), and more than 95% of the cells were CD3 positive.
T-cell proliferation. Cells were cultured with RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 2-mercaptoethanol (2-ME, 50 µM), penicillin (50 µg/ml), and streptomycin (50 µg/ml). Thymocytes (5 × 105 cells), splenic T cells, and lymph node T cells (105 cells) were cultured in 96-well plates and stimulated with human recombinant IL-6 (10 ng/ml) and an anti-CD3 monoclonal antibody (145-2C11, 100 ng/ml) for 72 h. The cultured cells were pulsed for the last 6 h with 0.5 µCi of 3H-labeled thymidine per well, followed by scintillation counting.
Cell death analysis. Splenic T or lymph node T cells (2 × 105 cells) were cultured in 96-well plates and stimulated with human recombinant IL-6 (10 ng/ml) and the anti-CD3 antibody (100 ng/ml) for 24 h. The cells were stained with fluorescein isothiocyanate (FITC)-conjugated annexin V and propidium iodide (PI) (ApoAlert annexin V-FITC apoptosis kit; Clontech) according to the manufacturer's protocol. Flow cytometric analysis was performed with a FACScalibur flow cytometer and Cell Quest software (Becton Dickinson).
| |
RESULTS |
|---|
|
|
|---|
Generation of mice harboring a stat3 gene with a
wild-type or mutant SBE in the stat3 gene promoter and a
-galactosidase-expressing cassette in the first intron.
To
examine whether the autoregulatory mechanism of the
stat3 gene operates in vivo and to demonstrate its
biological role, we designed two targeting constructs, one with a
wild-type stat3 promoter and one with the stat3
promoter containing a mutant SBE. In the first intron, the constructs
carried the
-galactosidase-neomycin resistance fusion gene with a
polyadenylation signal (
-geo) linked with a splice acceptor site
(SA
-geo) at the 5' end and flanked with two loxP
sequences (Fig. 1A). When correctly targeted by homologous
recombination, the promoter activity could be monitored by assaying the
-galactosidase activity. For the mutant SBE, we selected a point
mutation generating an NcoI site (mSBE, Fig. 1A and 1B) in
the SBE. The effectiveness of the mutation was verified by a
transient-transfection assay using HepG2 cells and the reporter gene
constructs with or without the mutated SBE. As shown in Fig. 1B, the
mutant SBE effectively lost its IL-6 responsiveness. ES cells with the
correctly targeted gene were selected by both Southern blot analysis
(Fig. 1C and 1D) and reverse transcription (RT)-PCR analysis, which
allowed us to detect the mRNA containing the first exon and the
correctly spliced sequence for
-galactosidase (data not
shown). Using these ES clones, we generated
hetero-stat3wtSBE
-geo and
-stat3mSBE
-geo mice.
Heterozygous stat3wtSBE
-geo
and stat3mSBE
-geo mice were
viable and fertile. Embryos with homozygous
stat3wtSBE
-geo alleles died
in utero (data not shown), and their phenotypes were similar to those
of the stat3-deficient mice reported previously (39), suggesting that the introduction of the SA
-geo
cassette disrupted the stat3 gene.
Promoter activity of wild-type and mutant stat3
promoters in mouse tissues.
To examine in vivo the promoter
activities of the wild-type and mutant mSBE stat3 promoters,
histological sections of various tissues from the
stat3+/wtSBE
-geo and
stat3+/mSBE
-geo mice were
subjected to
-galactosidase staining. Positive staining for
-galactosidase was easily detected in hepatocytes and in the kidney.
In the kidney, the cells having
-galactosidase activity were some
renal tubules and glomeruli (Fig. 2C and
D). Arterial walls were also positive for
-galactosidase (data not
shown). In the thymus, the cells containing detectable levels of
enzymatic activity were located mainly in the medulla regions, and most of them appeared to be nonlymphoid cells, although we do not
neglect that thymocytes expressed undetectable levels of enzymatic
activities (Fig. 2E and F). There was no apparent difference in
the expression patterns between the
stat3+/wtSBE
-geo
and stat3+/mSBE
-geo
mice (Fig. 2), although we observed some quantitative difference in
-galactosidase activity of whole tissues between the
stat3+/wtSBE
-geo and
stat3+/mSBE
-geo mice: the
basal activities of
-galactosidase in the lysates of the liver and
kidney from stat3+/mSBE
-geo
mice were 74.2 and 65.5% of the average activity of
stat3+/wtSBE
-geo,
respectively. We did not observe a difference in the basal activity in
the lysate of the thymus between the
stat3+/wtSBE
-geo mice and
stat3+/mSBE
-geo mice.
These results indicate that the mutation in the SBE affects the
basal stat3 promoter activity slightly in liver and
kidney, but not thymus (Fig. 2A to 2F). In the spleen, the cells
having detectable levels of
-galactosidase activity were found
mainly in the red pulp region (Fig. 3A)
and the perifollicular tissue of the lymph
nodes (data not shown). In the
stat3+/mSBE
-geo
mice, the cells having detectable levels of
-galactosidase were rare
(Fig. 3A). The
-galactosidase activity of the whole spleen lysate was also reduced in the
stat3+/mSBE
-geo
mice (40.1% of that of
stat3+/wtSBE
-geo
mice). Furthermore, intravenous injection of IL-6 enhanced the
-galactosidase activity in the red pulp region of the spleen of
stat3+/wtSBE
-geo
mice but not of the
stat3+/mSBE
-geo
mice (Fig. 3A). These results indicate that the autoregulation of the
stat3 gene through the SBE is important in cells
of the red pulp region for both basal and IL-6-induced expression. To identify these cells, we performed double staining of spleen sections with an anti-
-galactosidase antibody and antibodies recognizing cell
type-specific markers. As shown in Fig. 3B, the cells expressing detectable levels of
-galactosidase colocalized with CD31- or CD11b-positive cells but not CD45R- or CD4-positive cells. These data
suggest that the SBE-dependent autoregulation of the
stat3 gene is operating in endothelial cells or
macrophages of peripheral lymphoid organs.
|
|
Tissue-specific role for the SBE in basal and IL-6-induced
stat3 gene expression in vivo
To
examine the effect of the SBE mutation in endogenous
stat3 expression in vivo, we generated mice with a
mutant stat3 promoter in both alleles. To do so, the
floxed SA
-geo cassette was deleted by Cre recombinase by crossing
the stat3+/mSBE
-geo
mice with CAG-cre transgenic mice (31), generating mice
carrying the stat3mSBE allele
heterozygously (Fig. 1A, 4A, and 4B).
Homozygous stat3mSBE mice
(stat3mSBE/mSBE) were generated by
crossing the heterozygous mice with each other. One-quarter
of the mice born were stat3mSBE/mSBE,
in accord with Mendelian expectations, and grew normally, suggesting that autoregulation of the stat3 gene through the SBE is
not essential for development.
|
|
Antiapoptosis role for stat3 autoregulation in T
cells.
Because the IL-6-induced stat3
mRNA expression in thymocytes was dependent on the intact SBE
(Fig. 5A), we next examined the role played by
stat3 gene autoregulation in T cells, where
we evaluated the IL-6-induced mRNA expression profile,
DNA synthesis, and cell survival. T cells were obtained from
the thymus, lymph nodes, and spleen of wild-type and
stat3mSBE/mSBE mice. We
first analyzed the mRNA levels of the junB and
Pim-1 genes, which act immediately downstream of the
gp130-mediated STAT3 signal (11, 22, 23, 36).
Pim-1 has been reported to be involved in gp130-mediated
cell proliferation and survival (36). As shown in Fig. 5B,
after 3 h of IL-6 stimulation in vitro, the junB and
Pim-1 mRNAs were elevated in the thymocytes from
wild-type mice, whereas their induction was markedly reduced in the
thymocytes from the
stat3mSBE/mSBE mice (Fig.
5B). We next analyzed the effects of disrupting
stat3 gene autoregulation on IL-6-induced DNA
synthesis and cell survival. As shown in Fig.
6A and B, the anti-CD3
antibody given alone elicited similar DNA
synthesis responses in the thymocytes and splenic T cells from
both wild-type and
stat3mSBE/mSBE mice. In
contrast, costimulation with the anti-CD3 antibody and IL-6
consistently elicited less DNA synthesis in the thymocytes and
splenic T cells from the
stat3mSBE/mSBE mice than in
those from wild-type mice.
|
| |
DISCUSSION |
|---|
|
|
|---|
In this report, we provide the first evidence that the autoregulatory mechanism for stat3 gene activation through the low-affinity SBE in the promoter is critically required for IL-6-induced stat3 gene activation in a tissue-specific manner. The tissues and cells that required the autoregulatory mechanism for the IL-6-induced stat3 gene activation through the SBE were the kidney and spleen, especially the CD31- or CD11b-positive cells that are abundant in the spleen red pulp and the immature and mature T cells from the thymus, spleen, and LNs. Moreover, we showed that the autoregulatory loop of the stat3 gene activation is involved in the IL-6-induced protection from apoptosis and proliferation in both mature and immature T cells and for the maintenance in thymocytes of the mRNA expression of two STAT3 target genes, junB and Pim-1. In contrast, the SBE was not involved in IL-6-induced stat3 gene activation in hepatocytes. This result is not consistent with previous findings that the SBE is required for IL-6-induced activation of the stat3 gene promoter in HepG2 human hepatoma cells (16) (see also Fig. 1B). We do not yet understand the cause of this discrepancy. IL-6 generates various signals through gp130, including the STAT3-mediated signal and Ras-ERK mitogen-activated protein kinase (MAP kinase) cascade (15), and the latter may be involved in IL-6-induced stat3 gene activation in the liver. It is also possible that STAT3 may activate the stat3 gene in hepatocytes through an unidentified STAT3-binding site(s) in the stat3 promoter or some other region. STAT3 has been reported to interact with other transcription factors directly or indirectly, such as c-Jun, p300, and Smad1 (25, 33), and such STAT3 complexes may be involved in regulation of stat3 in the liver. It is also not known what determines tissue specificity in the autoregulatory mechanism. Elucidation of the IL-6-responsive element for stat3 expression in the liver will reveal this point. In any case, our data provide evidence that the stat3 gene is autoregulated by a tissue-specific mechanism.
The cells expressing detectable levels of
-galactosidase in the red
pulp of the spleen colocalized with CD31- and CD11b-positive cells.
Because these cells were abundant in the red pulp and the shapes of the
stained cells were streaky in many cases, they were likely to be
endothelial cells and macrophages. The SBE mutation reduced the basal
level of stat3 expression as well as the
IL-6-activated promoter activity in these cells (Fig. 2A). These cells
may therefore function as a sensor, detecting low levels of
circulating IL-6 in the blood. Alternatively, considering that splenic
endothelial cells produce IL-6 in vitro, they may respond to IL-6 that
is produced in an autocrine manner (40). It has been
reported that IL-6 acts on endothelial cells to increase their ability
to adhere to lymphocytes by enhancing their expression of ICAM-1,
VCAM-1, and E-selectin (30, 42), and a combination of IL-6
and soluble IL-6 receptor has been shown to stimulate endothelial cells
to activate STAT3, induce MCP-1 expression, and augment ICAM-1
expression (30). Therefore, STAT3-mediated signals are
likely to be involved in enhancing the adhesion for and
transendothelial migration of lymphocytes by increasing the expression
levels of certain adhesion molecules and chemokines. It has also been
reported that STAT3-deficient macrophages showed high sensitivity to
lipopolysaccharide (LPS) (37). It may be that
stat3 autoregulation is also involved in the
regulation of activation of macrophages.
Although the mutation in the SBE inhibited the autoregulation of the stat3 gene in several tissues, as described above, the development and function of those tissues in the stat3mSBE/mSBE mice were not significantly affected (data not shown). These results suggest that although the autoregulation of the stat3 gene can modify some of the IL-6-induced responses, it is not essential for the development and maintenance of most tissues.
Some transcription factors other than STAT3 have been shown to autoregulate their own genes. c-Jun together with ATF-2 activates the c-jun gene (20). MyoD1 activates the MyoD1 gene promoter through two proximal E-boxes located close to the MyoD1 core promoter (45). The autoregulation of genes by their own products provides a positive feedback regulation mechanism that may amplify the intensity and prolong the duration of signals.
When and in what situation is the autoregulation of stat3 required? To elucidate these, we have examined the LPS-induced production of nitric oxide and cytokines using peritoneal macrophages. We have not yet found significant differences in those assays between the wild-type and mutant mice (unpublished observation). However, in other conditions and/or in other assays, we might see differences. Next, we examined the status of T cells of stat3mSBE/mSBE mice in an IL-6-stimulated condition. Proliferation of thymocytes and splenic T cells in response to costimulation with anti-CD3 and IL-6 was significantly reduced (Fig. 6A), and IL-6-mediated prevention of the apoptosis of splenic and lymph node T cells was perturbed in stat3mSBE/mSBE mice. This situation is similar to that of T cells defective in stat3 expression, in which IL-6-induced cell proliferation is severely impaired (38). These data indicate that the proliferation of T cells in response to IL-6 requires the SBE-mediated autoregulation of the stat3 gene. Correlated with this, the IL-6-dependent expression of Pim-1 and junB was attenuated in T cells from the stat3mSBE/mSBE mice (Fig. 5B). In summary, we provide evidence that stat3 is regulated by the autoregulatory mechanism in vivo. It seems likely that this mechanism is involved in other biological responses to IL-6 or other factors that activate STAT3 in a variety of tissues.
| |
ACKNOWLEDGMENTS |
|---|
We thank R. Masuda and A. Kubota for secretarial assistance.
This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology in Japan and the Osaka Foundation for Promotion of Clinical Immunology. M.N. and K.N. are Research Fellows of the Japan Society for the Promotion of Science.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Molecular Oncology (C7), Osaka University Graduate School of Medicine, 2-2, Yamada-oka, Suita, Osaka 565-0871, Japan. Phone: 81-6-6879-3880. Fax: 81-6-6879-3889. E-mail: hirano{at}molonc.med.osaka-u.ac.jp.
Present address: Department of Restorative Dentistry and
Endodontology, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, Japan.
Present address: Unit on Vertebrate Neural Development, Laboratory
of Molecular Genetics, NICHD/NIH, Bethesda, MD 20892.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Akira, S., Y. Nishio, M. Inoue, X. J. Wang, S. Wei, T. Matsusaka, K. Yoshida, T. Sudo, M. Naruto, and T. Kishimoto. 1994. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77:63-71[CrossRef][Medline]. |
| 2. |
Boeuf, H.,
C. Hauss,
F. D. Graeve,
N. Baran, and C. Kedinger.
1997.
Leukemia inhibitory factor-dependent transcriptional activation in embryonic stem cells.
J. Cell Biol.
138:1207-1217 |
| 3. | Bowman, T., R. Garcia, J. Turkson, and R. Jove. 2000. STATs in oncogenesis. Oncogene 19:2474-2488[CrossRef][Medline]. |
| 4. | Catlett-Falcone, R., T. H. Landowski, M. M. Oshiro, J. Turkson, A. Levitzki, R. Savino, G. Ciliberto, L. Moscinski, J. L. Fernandez-Luna, G. Nunez, W. S. Dalton, and R. Jove. 1999. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10:105-115[CrossRef][Medline]. |
| 5. |
Chapman, R. S.,
P. C. Lourenco,
E. Tonner,
D. J. Flint,
S. Selbert,
K. Takeda,
S. Akira,
A. R. Clarke, and C. J. Watson.
1999.
Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3.
Genes Dev.
13:2604-2616 |
| 6. |
Chung, C. D.,
J. Liao,
B. Liu,
X. Rao,
P. Jay,
P. Berta, and K. Shuai.
1997.
Specific inhibition of Stat3 signal transduction by PIAS3.
Science
278:1803-1805 |
| 7. | Chung, J., E. Uchida, T. C. Grammer, and J. Blenis. 1997. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol. Cell. Biol. 17:6508-6516[Abstract]. |
| 8. |
Darnell, J. E., Jr.
1997.
STATs and gene regulation.
Science
277:1630-1635 |
| 9. |
Darnell, J. E., Jr.,
I. M. Kerr, and G. R. Stark.
1994.
Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.
Science
264:1415-1421 |
| 10. |
Friedrich, G., and P. Soriano.
1991.
Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice.
Genes Dev.
5:1513-1523 |
| 11. | Fujitani, Y., K. Nakajima, H. Kojima, K. Nakae, T. Takeda, and T. Hirano. 1994. Transcriptional activation of the IL-6 response element in the junB promoter is mediated by multiple Stat family proteins. Biochem. Biophys. Res. Commun. 202:1181-1187[CrossRef][Medline]. |
| 12. | Fukada, T., M. Hibi, Y. Yamanaka, M. Takahashi-Tezuka, Y. Fujitani, T. Yamaguchi, K. Nakajima, and T. Hirano. 1996. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity 5:449-460[CrossRef][Medline]. |
| 13. | Fukada, T., T. Ohtani, Y. Yoshida, T. Shirogane, K. Nishida, K. Nakajima, M. Hibi, and T. Hirano. 1998. STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J. 17:6670-6677[CrossRef][Medline]. |
| 14. | Hirano, T., K. Ishihara, and M. Hibi. 2000. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19:2548-2556[CrossRef][Medline]. |
| 15. | Hirano, T., K. Nakajima, and M. Hibi. 1997. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev. 8:241-252[CrossRef][Medline]. |
| 16. |
Ichiba, M.,
K. Nakajima,
Y. Yamanaka,
N. Kiuchi, and T. Hirano.
1998.
Autoregulation of the Stat3 gene through cooperation with a cAMP-responsive element-binding protein.
J. Biol. Chem.
273:6132-6138 |
| 17. | Ihara, S., K. Nakajima, T. Fukada, M. Hibi, S. Nagata, T. Hirano, and Y. Fukui. 1997. Dual control of neurite outgrowth by STAT3 and MAP kinase in PC12 cells stimulated with interleukin-6. EMBO J. 16:5345-5352[CrossRef][Medline]. |
| 18. | Ihle, J. N. 1996. STATs: signal transducers and activators of transcription. Cell 84:331-334[CrossRef][Medline]. |
| 19. | Jove, R. 2000. STAT signaling. Oncogene 19:2415-2616. |
| 20. |
Karin, M.
1995.
The regulation of AP-1 activity by mitogen-activated protein kinases.
J. Biol. Chem.
270:16483-16486 |
| 21. |
Kiuchi, N.,
K. Nakajima,
M. Ichiba,
T. Fukada,
M. Narimatsu,
K. Mizuno,
M. Hibi, and T. Hirano.
1999.
STAT3 is required for the gp130-mediated full activation of the c-myc gene.
J. Exp. Med.
189:63-73 |
| 22. | Kojima, H., K. Nakajima, and T. Hirano. 1996. IL-6-inducible complexes on an IL-6 response element of the junB promoter contain Stat3 and 36 kDa CRE-like site binding protein(s). Oncogene 12:547-554[Medline]. |
| 23. |
Nakajima, K.,
T. Kusafuka,
T. Takeda,
Y. Fujitani,
K. Nakae, and T. Hirano.
1993.
Identification of a novel interleukin-6 response element containing an Ets-binding site and a CRE-like site in the junB promoter.
Mol. Cell. Biol.
13:3027-3041 |
| 24. | Nakajima, K., Y. Yamanaka, K. Nakae, H. Kojima, M. Ichiba, N. Kiuchi, T. Kitaoka, T. Fukada, M. Hibi, and T. Hirano. 1996. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J. 15:3651-3658[Medline]. |
| 25. |
Nakashima, K.,
M. Yanagisawa,
H. Arakawa,
N. Kimura,
T. Hisatsune,
M. Kawabata,
K. Miyazono, and T. Taga.
1999.
Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300.
Science
284:479-482 |
| 26. | Narimatsu, M., K. Nakajima, M. Ichiba, and T. Hirano. 1997. Association of Stat3-dependent transcriptional activation of p19INK4D with IL-6-induced growth arrest. Biochem. Biophys. Res. Commun. 238:764-768[CrossRef][Medline]. |
| 27. |
Nicholson, S. E.,
D. De Souza,
L. J. Fabri,
J. Corbin,
T. A. Willson,
J. G. Zhang,
A. Silva,
M. Asimakis,
A. Farley,
A. D. Nash,
D. Metcalf,
D. J. Hilton,
N. A. Nicola, and M. Baca.
2000.
Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130.
Proc. Natl. Acad. Sci. USA
97:6493-6498 |
| 28. |
Niwa, H.,
T. Burdon,
I. Chambers, and A. Smith.
1998.
Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3.
Genes Dev.
12:2048-2060 |
| 29. | Ohtani, T., K. Ishihara, T. Atsumi, K. Nishida, Y. Kaneko, T. Miyata, S. Itoh, M. Narimatsu, H. Maeda, T. Fukada, M. Itoh, H. Okano, M. Hibi, and T. Hirano. 2000. Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. Immunity 12:95-105[CrossRef][Medline]. |
| 30. | Romano, M., M. Sironi, C. Toniatti, N. Polentarutti, P. Fruscella, P. Ghezzi, R. Faggioni, W. Luini, V. van Hinsbergh, S. Sozzani, F. Bussolino, V. Poli, G. Ciliberto, and A. Mantovani. 1997. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6:315-325[CrossRef][Medline]. |
| 31. | Sakai, K., and J. Miyazaki. 1997. A transgenic mouse line that retains Cre recombinase activity in mature oocytes irrespective of the cre transgene transmission. Biochem. Biophys. Res. Commun. 237:318-324[CrossRef][Medline]. |
| 32. | Sano, S., S. Itami, K. Takeda, M. Tarutani, Y. Yamaguchi, H. Miura, K. Yoshikawa, S. Akira, and J. Takeda. 1999. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. 18:4657-4668[CrossRef][Medline]. |
| 33. |
Schaefer, T. S.,
L. K. Sanders, and D. Nathans.
1995.
Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3.
Proc. Natl. Acad. Sci. USA
92:9097-9101 |
| 34. |
Schmitz, J.,
M. Weissenbach,
S. Haan,
P. C. Heinrich, and F. Schaper.
2000.
SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130.
J. Biol. Chem.
275:12848-12856 |
| 35. |
Seidel, H. M.,
L. H. Milocco,
P. Lamb,
J. E. Darnell, Jr.,
R. B. Stein, and J. Rosen.
1995.
Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity.
Proc. Natl. Acad. Sci. USA
92:3041-3045 |
| 36. | Shirogane, T., T. Fukada, J. M. Muller, D. T. Shima, M. Hibi, and T. Hirano. 1999. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 11:709-719[CrossRef][Medline]. |
| 37. | Takeda, K., B. E. Clausen, T. Kaisho, T. Tsujimura, N. Terada, I. Forster, and S. Akira. 1999. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10:39-49[CrossRef][Medline]. |
| 38. |
Takeda, K.,
T. Kaisho,
N. Yoshida,
J. Takeda,
T. Kishimoto, and S. Akira.
1998.
Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice.
J. Immunol.
161:4652-4660 |
| 39. |
Takeda, K.,
K. Noguchi,
W. Shi,
T. Tanaka,
M. Matsumoto,
N. Yoshida,
T. Kishimoto, and S. Akira.
1997.
Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality.
Proc. Natl. Acad. Sci. USA
94:3801-3804 |
| 40. | Teague, T. K., P. Marrack, J. W. Kappler, and A. T. Vella. 1997. IL-6 rescues resting mouse T cells from apoptosis. J. Immunol. 158:5791-5796[Abstract]. |
| 41. |
Teague, T. K.,
B. C. Schaefer,
D. Hildeman,
J. Bender,
T. Mitchell,
J. W. Kappler, and P. Marrack.
2000.
Activation-induced inhibition of interleukin 6-mediated T cell survival and signal transducer and activator of transcription 1 signaling.
J. Exp. Med.
191:915-926 |
| 42. | Watson, C., S. Whittaker, N. Smith, A. J. Vora, D. C. Dumonde, and K. A. Brown. 1996. IL-6 acts on endothelial cells to preferentially increase their adherence for lymphocytes. Clin. Exp. Immunol. 105:112-119[CrossRef][Medline]. |
| 43. | Yamanaka, Y., K. Nakajima, T. Fukada, M. Hibi, and T. Hirano. 1996. Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. EMBO J. 15:1557-1565[Medline]. |
| 44. | Yanagisawa, M., K. Nakashima, and T. Taga. 1999. STAT3-mediated astrocyte differentiation from mouse fetal neuroepithelial cells by mouse oncostatin M. Neurosci Lett. 269:169-172[CrossRef][Medline]. |
| 45. |
Zingg, J. M.,
G. Pedraza-Alva, and J. P. Jost.
1994.
MyoD1 promoter autoregulation is mediated by two proximal E-boxes.
Nucleic Acids Res.
22:2234-2241 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»